Opendata, web and dolomites

GlucoBeam

GlucoBeam: A portable device for pain-free glucose self-monitoring in diabetic patients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GlucoBeam project word cloud

Explore the words cloud of the GlucoBeam project. It provides you a very rough idea of what is the project "GlucoBeam" about.

savings    raman    society    relies    patients    sources    finger    carefully    billion    prick    diet    medium    ing    approx    world    aggregated    complications    life    severe    patient    health    turnover    device    strategy    diabetic    intake    costly    strip    market    uncomfortable    dm    modern    cured    signals    avoiding    painful    blood    smbg    30s    disposable    electrochemical    concentration    poor    times    rsp    ultimately    monitoring    double    onto    desired    compliance    mellitus    treatment    period    requiring    commercialization    scanning    tissue    conventional    acute    successful    detecting    day    invasive    lancet    exercise    significantly    position    leverage    refined    foothold    substances    quality    individual    382    self    risk    balancing    population    thereby    insulin    proprietary    pain    glucose    errors    collect    critical    droplet    optical    secure    digit    glucobeam    minimum    added    diabetes    spectroscopy    faced    innovation    levels    healthcare    repeating    minimizing    extract    therapy    right    253    people    empowering    post    cornerstone    million    leads   

Project "GlucoBeam" data sheet

The following table provides information about the project.

Coordinator
RSP SYSTEMS A/S 

Organization address
address: SIVLANDAENGET 27 C HJALLESE
city: ODENSE S
postcode: 5260
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website http://rspsystems.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-02-01   to  2016-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RSP SYSTEMS A/S DK (ODENSE S) coordinator 50˙000.00

Map

 Project objective

Diabetes mellitus (DM) is one of the largest health challenges currently faced by modern society, affecting 382 million people in the world. DM cannot be cured, but via well-controlled therapy, a high quality of life with diabetes can be obtained, with a minimum of short- and long-term complications. The key to a successful diabetes therapy is a well-controlled blood glucose level, which is obtained by carefully balancing insulin intake, diet, and exercise and with Self-Monitoring of Blood Glucose (SMBG) as a cornerstone. Conventional SMBG is an invasive test requiring the patient to prick his/her finger with a lancet to extract a blood droplet onto a disposable strip for electrochemical analysis of the glucose concentration. Repeating this uncomfortable and painful task 4-8 times per day leads to severe loss in life quality, often resulting in poor compliance leading to costly complications.

RSP’s proprietary non-invasive SMBG technology relies on the capabilities of Raman spectroscopy for directly detecting individual substances, refined by a unique critical depth optical scanning to collect glucose signals from the right tissue depth range, thus avoiding sources of errors during the measurement. Our GlucoBeam device will enable DM patients to test their glucose levels in around 30s and as often as desired – at no added cost or pain – thereby empowering them to better manage their treatment and minimizing the risk for acute complications.

GlucoBeam’s successful commercialization will position RSP to secure an aggregated turnover of approx. €253 million over the 5 years post-project period. Furthermore, it has the potential to reach double digit billion savings for EU’s healthcare systems and will ultimately lead to significantly improved life quality for the large population of diabetic patients. Moreover, GlucoBeam’s commercialization will allow RSP to set a market foothold in order to leverage its medium term innovation strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLUCOBEAM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLUCOBEAM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More